This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About scPharmaceuticals Stock (NASDAQ:SCPH) Get scPharmaceuticals alerts:Sign Up Key Stats Today's Range$5.67▼$5.6750-Day Range$5.50▼$5.7552-Week Range$2.20▼$6.28VolumeN/AAverage Volume953,834 shsMarket Capitalization$302.20 millionP/E RatioN/ADividend YieldN/APrice Target$5.68Consensus RatingReduce Company Overview scPharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing innovative therapies for sickle cell disease. The company’s lead product candidate, SC411, is an investigational intravenous formulation of a hemoglobin polymerization inhibitor designed to rapidly increase hemoglobin oxygen affinity and potentially reduce the severity and duration of vaso‐occlusive crises. By delivering a water‐soluble prodrug directly into the bloodstream, scPharmaceuticals aims to address an acute unmet need in emergency and inpatient settings where swift intervention can improve patient outcomes. In addition to SC411, scPharmaceuticals is advancing a pipeline of small‐molecule candidates that target different aspects of red blood cell pathology in sickle cell disease. The company’s research and development efforts leverage proprietary prodrug technology to enhance delivery and bioavailability, with the goal of providing both acute crisis interventions and chronic disease management options. scPharmaceuticals collaborates with academic institutions and clinical research organizations to conduct Phase 1 studies and plans to initiate later‐stage trials upon successful completion of early safety and pharmacokinetic assessments. Headquartered in Cambridge, Massachusetts, scPharmaceuticals was founded to translate cutting‐edge science into practical treatments for patients suffering from sickle cell disease. The company’s leadership team comprises industry veterans with experience in hematology, drug development and regulatory affairs. While initially focused on the U.S. market, scPharmaceuticals has stated its intention to expand clinical programs internationally as it progresses toward potential product approvals.AI Generated. May Contain Errors. Read More Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCPH Stock News HeadlinesMannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's ChangedMay 8, 2026 | finance.yahoo.comscPharmaceuticals Inc. Common Stock (SCPH)April 17, 2026 | nasdaq.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.May 22 at 1:00 AM | Porter & Company (Ad)MannKind initiated with a Buy at TruistNovember 24, 2025 | msn.comMannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline ExpansionNovember 8, 2025 | finance.yahoo.comMannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales MattersNovember 5, 2025 | msn.comMannKind outlines FUROSCIX market expansion and Afrezza pediatric launch strategy following record $82M Q3 revenueNovember 5, 2025 | msn.comMannKind completes acquisition of scPharmaceuticalsOctober 7, 2025 | msn.comSee More Headlines SCPH Stock Analysis - Frequently Asked Questions How were scPharmaceuticals' earnings last quarter? scPharmaceuticals, Inc. (NASDAQ:SCPH) posted its earnings results on Thursday, August, 7th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.04. The company earned $16.04 million during the quarter, compared to analysts' expectations of $15.41 million. scPharmaceuticals had a negative net margin of 183.55% and a negative trailing twelve-month return on equity of 1,647.86%. Read the conference call transcript. When did scPharmaceuticals IPO? scPharmaceuticals (SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that scPharmaceuticals investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/07/2025Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SCPH's financial health is in the Green zone, according to TradeSmith. SCPH has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCPH CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees30Year Founded2014Price Target and Rating Average Price Target for scPharmaceuticals$5.68 High Price Target$6.00 Low Price Target$5.35 Potential Upside/Downside+0.1%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$85.15 million Net Margins-183.55% Pretax Margin-183.55% Return on Equity-1,647.86% Return on Assets-71.76% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.14 Sales & Book Value Annual Sales$49.97 million Price / Sales6.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book21.00Miscellaneous Outstanding Shares53,298,000Free Float50,750,000Market Cap$302.20 million OptionableOptionable Beta0.31 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:SCPH) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked Amer...InvestorPlace | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
